收藏 分销(赏)

FDA检查表中文.doc

上传人:可**** 文档编号:966238 上传时间:2024-04-09 格式:DOC 页数:23 大小:304.50KB
下载 相关 举报
FDA检查表中文.doc_第1页
第1页 / 共23页
FDA检查表中文.doc_第2页
第2页 / 共23页
FDA检查表中文.doc_第3页
第3页 / 共23页
FDA检查表中文.doc_第4页
第4页 / 共23页
FDA检查表中文.doc_第5页
第5页 / 共23页
点击查看更多>>
资源描述

1、Private or Joint Label Supplier Assessment Checklist 私人公司或合资公司供应商评估清单 私人公司或合资公司供应商评估清单 私人公司或合资公司供应商评估清单 Audit Date(s) _ 审计日期(县) _ 审核日期 审核日期 Performed by 由 被审核者 被审核者 General Information: 一般信息: 基本信息 基本信息 Company (公司名称) _ 公司 (公司名称) _ Address (地址) _ 地址 (地址) _ Manufacturing site address: 工厂地址: (生产厂地址) (生

2、产厂地址) Is this the exact address of where the products are manufactured? 这是确切地址在哪里制造的产品? Yes 是 No 否 是这确切的地址产品是制作的地方 是这确切的地址产品是制作的地方 If no, what is the address? 如果没有,什么是地址? 如果没有,什么是地址? _ 如果没有,什么是地址? _ _ _ _ _ Key Contact _ 主要联系人_ Title_ Title_ Phone _ 电话_ FAX _ 传真_ e-mail _ 电子邮件: _ Key Contact _ 主要联系人

3、_ Title _ 标题_ Phone _ 电话_ FAX _ 传真_ e-mail _ 电子邮件: _ Is the manufacturing site facility registered with the US Food and Drug Administration (FDA)? 是工厂设施登记的美国食品和药物管理局( FDA ) ? No 否 Yes 是 Registration # _ 登记号: _ Has the facility ever been inspected by the FDA? 有过工厂视察美国食品和药物管理局? No 否 Yes 是 Date _ 日期_ W

4、as a FDA 483 issued? 483是美国FDA发出? No 否 Yes 是 If yes, ask to review the FDA 483 form and the companys response to the FDA 483. 如果有,请审查林业局483形式和该公司的回应美国食品和药物管理局483 。 Additionally, review any letters that the company may have received following the inspection to determine whether the FDA considers the

5、inspection closed. 此外,审查的任何信件,该公司可能会收到以下检查以确定是否认为美国FDA检查封闭。 Verify that any corrective actions in response to FDA 483 observations that relate to products made for Cardinal Health are effectively implemented. 确认任何纠正行动回应美国FDA 483的意见,即涉及到的产品为枢机健康的有效实施。 Has the firm received a warning letter from FDA?

6、该公司已经收到了来自美国FDA的警告信? No 否 Yes 是 Date _ 日期_ If yes, ask to review the FDA Warning Letter and the companys response to the Warning Letter. 如果是的话,请检讨美国FDA的警告信和该公司的反应,警告信。 Additionally, review any letters that the company may have received from FDA to determine whether the FDA considers the Warning Lett

7、er closed. 此外,审查的任何信件,该公司可能已收到来自美国FDA ,以确定是否认为美国食品和药物管理局警告信封闭。 Verify that any corrective actions in response to Warning Letter that relate to products made for Cardinal Health are effectively implemented. 确认任何纠正行动响应警告信中涉及的产品为枢机健康的有效实施。 Does the company have a US Agent? 这家公司有美国的代理? No 否 Yes 是 US Age

8、nt name and address: _ 美国代理的名称和地址: _ ISO Registration? 国际标准化组织登记? No 否 Yes 是 Standard _ 标准_ Registrar _ 书记官长_ Date _ 日期_ Facility size (square feet) _ 基金规模(平方英尺) _ Number of employees _ 雇员人数_ Number of Quality Management employees _ 一些质量管理员工 _ Number of production shifts per day _ 一些生产转移每天_ Producti

9、on days per week _ 生产天每周_ Management Responsibility: 管理责任: 1. 1 。 Does the firm have a Quality Policy that defines approaches, objectives, and, management commitment? 请问该公司的质量方针政策,定义,目标和管理的承诺? No 否 Yes 是 a) 一) At what management level in the firm is the Quality Policy approved? 在什么管理水平的公司的质量方针批准? _

10、_ _ _ b) 二) How is the Quality Policy communicated to employees? 是怎样的质量方针传达给员工? _ _ _ _ c) 三) What method is used to assure that employees understand the Quality Policy? _ 什么方法,以确保员工的质量方针的理解? _ 2. 2 。 How are authority and responsibility assigned? 如何分配权力和责任? If available, obtain an organization char

11、t, which illustrates where the Quality Management function reports. _ 可以的话,获得的组织结构图,这说明在质量管理职能的报告。 _ _ _ a) 一) Does the company have a permanent Quality Management function? 这家公司有一个固定的质量管理功能? No 否 Yes 是 i) 一) Does QM function independently of the production unit? 没有质量管理职能独立于生产部门? No 否 Yes 是 ii) 二) I

12、f no organizational chart is available, to whom does QM report? _ 如果没有组织结构图的情况下,质量管理,以谁报告? _ b) 二) Has management with executive responsibility assigned a Management Representative? 有管理的行政责任指派一个管理代表? No 否 Yes 是 i) 一) Who is the Management Representative? _ 谁是管理代表? _ ii) 二) Is the assignment of the M

13、anagement Representative formally documented? 是转让管理代表正式记录? No 否 Yes 是 3. 3 。 Is the suitability and effectiveness of the Quality System evaluated by management with executive responsibility? 是的适宜性和有效性进行评估的质量体系进行管理与行政责任? No 否 Yes 是 a) 一) Does a written policy describe the frequency and content of the

14、 review of the Quality System? 是否有书面的政策描述的频率和内容的审查质量管理体系? No 否 Yes 是 b) 二) How does management implement corrective action? 如何管理实施纠正行动? _ _ _ _ c) 三) Is the result of the Quality System evaluation documented? 是由于质量体系评价记录? No 否 Yes 是 4. 4 。 Is the Quality System described in writing? 是质量体系的书面说明? No 否

15、 Yes 是 a) 一) Does the firm have a Quality Manual? 请问该公司的质量手册? No 否 Yes 是 b) 二) Who approves the Quality Manual? 谁批准了质量手册? (Name _ Title _)? (名称_标题_)? c) 三) How are current copies of the Quality Manual made available to personnel? 如何目前副本的质量手册提供给工作人员? _ _ _ _ d) 四) Does the Quality Manual contain or r

16、eference all procedures and forms used to document the quality system? 请问质量手册包含或引用的所有程序和形式用于文件的质量管理体系? No 否 Yes 是 5. 5 。 Are written procedures utilized to carry out the requirements of the Quality Manual? 写程序来进行的要求,质量手册? No 否 Yes 是 Design Control: 设计控制: 1. 1 。 Does a written procedure describe how

17、the design input requirements for a new product, including the needs of the user, are identified, documented, reviewed, and approved. 是否有书面程序描述如何设计输入要求的新产品,包括需要的用户,确定,记载,审查和批准。 No 否 Yes 是 2. 2 。 Does a written procedure describe how the design outputs for a new product are compared with the design i

18、nput requirements to ensure completeness and clarity of the design? 是否有书面程序描述如何设计产出的新产品进行了比较与设计输入的要求,以确保完整和清晰的设计? No 否 Yes 是 a) 一) Are the design outputs reviewed to ensure compliance with relevant standards and regulatory requirements? 产出的设计审查,以确保遵守有关标准和法规的要求? No 否 Yes 是 3. 3 。 Design verification

19、and validation: 设计验证和确认: a) 一) Is there a written process for identification of process or product parameters and tolerances that will be used, during production, to assure product conformance with design requirements 是否有书面程序鉴定过程或产品的参数和公差将使用,生产过程,以确保产品符合设计要求 No 否 Yes? 是吗? b) 二) Have processes that c

20、annot be verified by subsequent inspection been identified and validated? 有进程,无法加以核实以后的检查确认和验证? No 否 Yes 是 Describe the process associated with product with Cardinal Health labeling that have been validated: _ 描述的过程与产品,卡地纳健康标签已验证: _ _ _ c) 三) Are labels designed, printed, and applied so that they re

21、main legible and attached during storage, distribution, and use ? 是标签设计,印刷,和应用使它们保持清晰和重视在储存期间,分配和使用 ? No 否 Yes 是 i) 一) Are roll labels (desirable) used instead of cut labels? 正在推出的标签(可取)代替削减标签? No 否 Yes 是 d) 四) Are initial production units, lots, or batches of finished device tested: 是初次生产的单位,地段,或批完

22、成设备测试: i) 一) Under simulated or actual use conditions? 在模拟或实际使用条件? No 否 Yes 是 ii) 二) For effects of storage conditions? 影响的储存条件? No 否 Yes 是 iii) 三) For effects of shipping conditions? 影响的航运条件? No 否 Yes 是 e) 五) Has a useful life been established for the product? 具有使用寿命已建立的产品? No 否 Yes 是 i) 一) Are exp

23、iration dates established for each product? 截止日期是确定的每个产品的? No 否 Yes 是 Are there written test procedures for the establishment of an expiration date? 是否有书面测试程序建立一个有效截止日期? No 否 Yes 是 Are test results documented and retained in the Design History File? 有测试结果记录在案,并保留在设计历史文件? No 否 Yes 是 ii) 二) Is stabili

24、ty data on file to substantiate the dating plus other claims? 是稳定的数据文件,以充实约会加上其他索赔? No 否 Yes 是 f) 女) Has a review been made of the components that constitute a device to determine which components should be traceable back to receiving to ensure the protection of the public health? 已审查已取得的组成部分,构成了设备,

25、以确定哪些部分应该追溯回接收,以确保保护公众的健康? No 否 Yes 是 g) 克) Is a medical device listing (FD2892) performed twice yearly for changes in the status of products? 是一家医疗设备清单( FD2892 )进行每年两次的变化状况的产品吗? No 否 Yes 是 4. 4 。 Does an individual not having responsibility for design activity being reviewed formally review and app

26、rove the design output? 是否个人没有责任,设计活动正在审查正式审查和批准的设计输出? No 否 Yes 是 5. 5 。 Is a written procedure utilized to formally approve a design and transfer the design to production? 是一种书面程序,以正式批准使用的设计和转让的设计到生产的? No 否 Yes 是 a) 一) Has the firm identified the operations where key product characteristics are con

27、trolled? 该公司已经确定了行动,主要产品特点是控制? No 否 Yes 是 b) 二) Has major equipment been identified? 主要设备已被确认? No 否 Yes 是 c) 三) For the products manufactured with Cardinal Health labeling list the major equipment: 生产的产品标签与红衣主教健康的主要设备清单: _ _ d) 四) Does the firm have a control strategy and specifications for key proc

28、ess variables? 是否有该公司的控制策略和规格的关键过程变量? No 否 Yes 是 e) 五) Are the inspections performed based on statistically valid sampling plans (eg ANSI Z-1.4, Mil Std 105E, zero defects, SPC, etc.) of the product or process? 正在检查的基础上进行有效的统计抽样计划(如标准的Z - 1.4 ,军医标准105E ,零缺陷,最高人民法院等)的产品或进程? No 否 Yes 是 i) 一) Has a cla

29、ssification of defects (listing of possible defects) including level of severity been established for the product? 有一个分类的缺陷(缺陷可能上市) ,其中包括的严重程度已建立的产品? No 否 Yes 是 ii) 二) Have process limits been established for validated processes? 有进程的限制,建立验证程序? No 否 Yes 是 6. 6 。 Do procedures exist that describes th

30、e process used to authorize change to a design after the design has been transferred to production? 这样的程序存在,说明所采用的程序批准的设计变更后的设计已经被转移到生产? No 否 Yes 是 a) 一) What levels of approval are required? _ 什么样的审批要求? _ b) 二) Does the process ensure that product or process changes do not adversely affect customer

31、 requirements? 是否进程确保产品或过程的变化不影响客户的需求? No 否 Yes 是 c) 三) Does a written procedure require approval from Cardinal Health before any changes are implemented on private label product? 是否有书面程序要求批准枢机健康的任何变化都在实施自有品牌的产品? No 否 Yes 是 d) 四) Do procedures require review of applicable regulatory documents (PMA, 510(k), etc.) before changes are implemented? 做程序要求审查适用的法规文件(物业, 510 (金)等)实施前的变化? No 否 Yes 是 e) 五) What records retained as part of the product design history file. 什么记录保留的一部分,产品设计的历史档案。 _ _ _ _ _ _ _ _ Purchasing: 采购: 1. 1 。 Do written procedures for

展开阅读全文
相似文档                                   自信AI助手自信AI助手
猜你喜欢                                   自信AI导航自信AI导航
搜索标签

当前位置:首页 > 包罗万象 > 大杂烩

移动网页_全站_页脚广告1

关于我们      便捷服务       自信AI       AI导航        获赠5币

©2010-2024 宁波自信网络信息技术有限公司  版权所有

客服电话:4008-655-100  投诉/维权电话:4009-655-100

gongan.png浙公网安备33021202000488号   

icp.png浙ICP备2021020529号-1  |  浙B2-20240490  

关注我们 :gzh.png    weibo.png    LOFTER.png 

客服